Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-3 Phase 1 single ascending dose in healthy volunteers
NCT06770491Phase 1Completed
- Sponsor
- NeuroDawn
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Y-3 for injection with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time Zero to Last Measurable Concentration and 9 more. Started Feb 2025; status: completed.
02
Drugs
loberamisal
Beyond the preview
Go deeper on NCT06770491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770491.